The New Progress in Cancer Treatment

By Xu Ze, Xu Jie, Bin Wu and Lily Xu

In the half century after the Second World War, oncology has developed greatly both in the world and in China. There are three traditional major treatments: surgery, which has been used to treat tumors for more than a hundred years; radiotherapy, which has been used for ninety years; and chemotherapy, which has been used for nearly seventy years. In the 1980s, there was the rise of biological therapy and immunotherapy. The effects of oncological therapy have made a lot of progress. Many tumors have achieved good results, but there are still many solid tumors whose efficacy are still very poor.

In 1985, the author followed up more than three thousand patients who had undergone the general surgical operation and thorax surgical operation. The results showed that most patients relapsed and metastasized within two to three years after surgery. Some patients even relapsed in a few months. This made me deeply realize that surgery is successful and standardized, but the long-term effect is not satisfied or that the long-term treatment is a failure.

• Language: English
• Publisher: AuthorHouse
• Release date: Jun 28, 2018
• ISBN: 9781546247593

Xu Ze

Xu Ze, male, was born in Leping County, Jiangxi Province, on October 1933. He graduated from Tongji Medical University in 1956 and successively held the posts of director of department of surgery of Affiliated Hospital of Hubei College of Traditional Chinese Medicine, professor, chief physician, tutor of postgraduate and doctoral students, president of Experimental Surgery Restitute Institute of Hubei College of Traditional Chinese Medicine, director of Abdominal Tumor Surgery Research Room, and Director of Anti-Carcinomatous Metastasis and Reoccurrence Research Room. In addition, he held concurrent posts of standing director of China Medical Association Wuhan Branch, vice president of Wuhan Micro-Circulation Academy, academic member of International Liver Disease Research, Cooperation and Exchange Center, member of International Surgeon Union, standing member of first, second, third, and fourth editorial board of China Experimental Surgery Journal, standing member of first, second, and third editorial board of Abdominal Surgery Journal. He is enjoying Special Allowance of State Council. He has been engaged in surgery work for forty-nine years and accumulated rich experience in radical operation of lung cancer, esophageal carcinoma, liver cancer, carcinoma of gallbladder, adenocarcinoma of pancreas, gastric carcinoma, and intestinal cancer, as well as in clinical therapy with Chinese traditional medicine combined with Western medicine of prevention of reoccurrence and metastasis after operation. Xu Jie, male, graduated from Hubei College of Traditional Chinese Medicine in 1992. He graduated from the Department of Clinical Medicine in Hubei Medical University in 1996. Now he is chief physician in Hubei University of Traditional Chinese Medicine Hospital and Hubei Provincial Hospital of Surgery. He is engaged in experimental surgical tumor research, general surgery, and urology clinical work. Bin Wu, MD, PhD, graduated from College of Yunyang of Tongji University of Medical Sciences for her MD degree. She studied her masters degree and her PhD in Sun Yat-Sen University of Medical Sciences. After she received her PhD, she worked as a postdoctoral fellow in the John Hopkins Medical School and University of Maryland Medical School. She passed all of her USMLE tests and is going to do her residency training in America. She dedicates herself to oncology clinical and research. Her goal is to conquer cancer, which she believes is great contribution to our health. She has a daughter, Lily Xu.

Book preview

© 2018 Xu Ze; Xu Jie; Bin Wu. All rights reserved.

No part of this book may be reproduced, stored in a retrieval system, or transmitted by any means without the written permission of the author.

Published by AuthorHouse 06/27/2018

ISBN: 978-1-5462-4760-9 (sc)

ISBN: 978-1-5462-4759-3 (e)

Library of Congress Control Number: 2018907202

Any people depicted in stock imagery provided by Getty Images are models,

and such images are being used for illustrative purposes only.

Certain stock imagery © Getty Images.

Because of the dynamic nature of the Internet, any web addresses or links contained in this book may have changed since publication and may no longer be valid. The views expressed in this work are solely those of the author and do not necessarily reflect the views of the publisher, and the publisher hereby disclaims any responsibility for them.

Contents

Introduction to This Book

A Brief Introduction to The first Author

A Brief Introduction to the Second Author

A brief introduction to the third author and the main translator and one of the editors

A Brief introduction to the illustrator and the advisor

Foreword

Acknowledgements

Chapter I         The New Understanding of Cancer Concept

Part I                 Cancer Therapy Should Be Built on the Understanding of the Concept of Cancer

Part II                The cure should be through the regulation and control rather than killing

Part III              The New Progress of Cancer Research and The New Trends of Treatment

Chapter II        The Retrospect and Prospect of Traditional Therapy and Medical Practices of Cancer

Part I                 The cases which the postoperative adjuvant chemotherapy failed to prevent recurrence

Part II                The Cases which the Postoperative Adjuvant Chemotherapy Failed to Prevent Metastasis

Part III              The Cases which Chemotherapy Accelerated Immune Function Failure

Chapter III      The Analysis, Evaluation and Reflection of Clinical Cases

Part I                 The basic concept of cancer cell proliferation kinetics and the role of chemotherapy drugs in the cell cycle

Part II                The analysis, reflects and evaluation of the entire immune suppression from chemotherapy

Part III              The Analyze, Reflect and Evaluate from Drug Resistance

Chapter IV      Chemotherapy needs further Research and improvement

Part I                 There are some important misunderstandings in current chemotherapy

Part II                The main contradiction of the current chemotherapy

Chapter V        The Experimental Research on Finding The New Anticancer Drugs from Natural Medications

Part I                 The Experimental Methods for Finding New Cancer Drugs from Natural Medications

Part II                The Understanding and Discussion of Seeking The New Anticancer Drug Experiments

Chapter VI      The Experimental Study of The Effect of Fuzheng Peiben on Inhibiting Tumor and Enhancing Immune Function in S180 Mice

Part I                 The Experimental Observation of Anti-tumor Effect of FuZheng PeiBen on S180 Mice

Part II                The Experiment Observation of the Effect of Pregnancy on the Tumor Growth of in Tumor-bearing S180 Mice

Chapter VII     The New Concepts and New Models of XZ-C Cancer Treatment

Part I                 To Strengthen Supportive Therapy and To Reduce the toxic side effects of chemotherapy

Part II                To Change From The Interval without Treatment into Continuous Treatment

Part III              To change the therapy from damaging the host into protecting the host

Part IV              Changing the balance between the tumor and the host and striving the imbalance into the balance

Part V                To Change from damaging the central immune organs into protecting the central immune organs

Part VI              To Change the therapy from the injury therapy into the non-injury therapy

Part VII             The New Concepts and Models of XZ-C Therapy for Anti-cancer Metastasis

Part VIII            XZ-C immunomodulating Chinese medications are the result of the modernization of traditional Chinese medications

Chapter VIII   The Observation of the Experimental and Clinical Efficacy of Treatment of Malignant Tumors with XZ-C anti-cancer Chinese Medications

Part I                 The Animal Experimental Research

Part II                The Clinical application observation

Part III              The Discussion of the experiment and clinical curative effect of XZ-C anti-cancer Chinese medications

Part IV              The Research of XZ-C4 Anti-cancer Drugs Inducing Cytokines

Chapter IX      The Typical Cases of Malignant Tumors Treated by XZ-C Immune Regulation and Control Traditional Chinese Medications

Part I                 The partial typical cases of treating Liver cancer

Part II                The Typical Cases of Treating Gastric Cancer

Part III              The Typical Cases of Postoperative Adjuvant Treatment of Lung Cancer

Part IV              The Typical Cases of Postoperative Adjuvant Therapy for Esophageal Cancer

Part V                Typical Cases of Postoperative Adjuvant Therapy for Breast Cancer

Part VI              Typical Cases of Postoperative Adjuvant Treatment of Colorectal Cancer and Rectal Cancer

Part VII             Typical Postoperative Adjuvant Treatments for Pancreatic Carcinoma, Gallbladder Carcinoma, Duodenal Cancer, and Ovarian Cancer

Part VIII            Typical Cases of Postoperative Adjuvant Treatment of Bladder Cancer

Chapter X        To Explore the mechanisms of cancer invasion, recurrence and metastasis and to search the effective measures for regulation and control

Part I                 The Experimental Study on Making Cancer Animal Models

Part II                The Relationship Between Tumors and Immune Organs

Part III              To investigate the methods of halting or stopping the atrophy of the thymus during tumor progression and to find ways to reconstruct the immune function system

Part IV              Seeking the drugs that inhibit tumor neovascularization from natural medications

Part V                The Possible causes and countermeasures of metastatic liver cancer after radical gastrectomy or radical excision of gastrointestinal cancer

Part VI              The reasons and control of recurrence and metastasis after radical resection of digestive tract cancer

Part VII             Focusing on the prevention and treatment of recurrence and metastasis after resection of liver cancer

Part VIII            Taking the various measures to treat the unresectable abdominal tumors

Part IX              Several problems that should be noticed in surgical treatment of the middle and lower rectal cancer

Chapter XI      The Effects of Spleen on Tumor Growth and Anticancer Effect of Chinese Herbs Jianpi Yiqi Decoction

Part I                 The Experimental Study on the Effect of Spleen on Tumor Growth

Part II                The Experimental Observation of the effects of tumor on the immune organs Thymus and Spleen

Part III              The Experiment of Anti-cancer Effect of Chinese Herbs Jianpi Yiqi Decoction

Chapter XII     The Inhibitory Effects of the extract of Yellow Rattan Vinyl Acetate (TG) on the neovascularization(angiogenesis) of transplanted tumors in mice

Part I                 The Experimental Study on the Observation of the Neonatal microvasculature(Angiogenesis) of Transplantation Tumor at the mice abdominal muscle

Part II                The experimental study on the effects of the different doses of TG on immune function in mice

Part III              The Experimental study of the inhibition of the different dosages of the extract of Yellow Rattan Vinyl Acetate (TG) on the neonatal microvasculature(angiogenesis) of the transplantation tumor at the mice abdominal muscle

IV                      The Significance of Inhibiting Tumor Angiogenesis in Treatment

Chapter XIII   The experimental research of the combined transplantation of the fetal liver, fetal spleen and fetal thymocytes with adoptive immune reconstruction for the treatment of malignant tumors

Part I                 The Experiments of the treatment of malignant tumors with Adoptive immune reconstruction through the Fetal liver, spleen, and thymus cells co-transplantation

Part II                The Progress of Study on Treatment of Tumor by Adoptive Immunotherapy through Transplantation of Immunocyte with the Origin of Embryo

Chapter XIV   Further Exploring the Novel Types of Chinese Pharmaceuticals for Anti-cancer Invasion, anti-metastasis and anti-relapse

Part I                 The reasons and main backgrounds at home and abroad to further explore and develop anti-cancer and anti-cancer herbal medications

Part II                The research prospects of anti-tumor plant drug

Chapter XV     The Review and Prospect of Surgical Oncology Treatment

The Main Reference Literature

Introduction to This Book

Bin Wu

All roads lead to Rome. Like some other things, there are many methods which can be used to treat Cancer. Cancer Immune therapy has been there for years. For instance, in the 1930s Willam Coley and their successors Coley Nauts treat the advanced cancer with Coley toxins. More than 200 cases of various types of cancer patients can be analyzed, which more than 30 cases were cured, and life more than 30 years. In the early 1980s Guesada and others treated hairy cell leukemia with IFN-a, which actually made the treatment effective (complete remission /CR + PR/ partial remission) reach over 90%. In this book there are the complete animal and clinical experiments about our immune regulation and control cancer therapy. This book deeply and clearly described the new understanding about cancer characteristics and how our body responds to cancer. Based on all of these comprehensive understanding about cancer, we searched the new therapy: the rules are to protect our body immune function and to regulate and to control cancer by re-balance the host and cancer instead of only focusing on killing the cancer cells.

Many main concepts and ways were published more than 20 years ago. Why do we want to publish this book in English after almost 20 years of this original book was published in Chinese in 2000? After 20 years of the application and practice to verify our concepts and our medications and the improvement during our practice, we walked out one way of conquering the cancer and of prolonging our cancer patient life term and enhancing the life quality. We believe that many cancers can be controlled very well and be cured after we worked hard to take care of them and our treatment goal for the cancer patient is that the patients have good life quality and live as the long term as the average normal persons. How do we tell our new treatment make the cancer patients live longer than the others who were treated by other methods? We compared our 5-survival rates with other cancer therapy method’s five year survival rates. Many patients can live very well with the cancer after taking our medications. For the cure efficacy and malignancy degree, we don’t use the tumor size as the criteria because the big tumor doesn’t mean more malignant (maybe there are some degree of necrosis in the tumor center); the small tumor doesn’t mean less malignant. The patient can live with the cancer and the patient can go back to work and can act the normal life under our medications.

Eventually, it achieves: 1/3 can be cured, 1/3 can be prevented; 1/3 can live with tumor.

In this book we concluded many of the original data from our animals and clinical experimental applications of our new methods. We realized that our body immune function played great roles in protecting our body healthy situation and did completely animal experimental test to test our immune system function, especially two main immune organs: bone morrow and thymus. T-cell was named after Thymus because T-cell will become mature in Thymus. In this book, we found that cancer is the immune function decreasing disease and HIV is the immune function deficience disease, both of which are the immune function diseases.

How to bring back our immune function is the main issue which we searched for. First, we tried to transplant the fetal immune organs to the cancer animals which we found that in some of the cancer animals after transplanting the immune organs the cancers can be gone away. However, all of the fetal organs experiments were barred because of the law rules. Later we worked extremely hard to look for all of the anti-cancer medications from the natural plants. We found many of the good effective medications on the regulations and controlling immune functions for the cancer patients; in the mean while, we continued and repeated and reformed all of the effective medication during our more than 20 years of practice. After more than 30 years of the application, we are successful and confident on our regulation and controlling immune function medications to prevent and to treat the cancers.

In this book you can learn all of our new concepts and new way to control the cancers. That day I attended a lecture about T-cell at the HIV patient and learned many of researcher and hospital to use T-cell to treat cancer and to treat HIV patients, which all confirm our new immune concepts and ways to cure the cancer. Our new cancer theory works and benefits to our patients. Each medication is very stable and has great protection for our body. So far our medications do not have any toxic to our human body. Many of our patients can go back to work as the normal person. Once again, as the proverbs all roads can lead to Roman. We found our ways to conquer the cancer. There will be the reason for anything to happen. Science is endless. We need to do more research to understand the reason for the diseases so that we can control them well and we can help the patients more and reduce their anxiety and make them live happier and longer.

In brief, our new treatment and new medications work very successfully for the cancer patients after more than decade applications. Our theory and concept of treatment work very well on regulating and controlling the cancers.

Finally, thank authorhouse press give us great help to publish this book internationally. This book was finished during such shortly several months and is full of many new knowledge and the innovative concepts so that maybe there are mistakes which we please can be forgiven for this and will also appreciate for any feedback.

Bin Wu, M.D., Ph.D

05-14-2018

In Timonium, MD in USA

A Brief Introduction to The first Author

image002.jpg

Xu Ze, male, born in Leping County of Jiangxi Province in Oct. 1933, graduated from Tongji Medical University in 1956, successively held the post of director of department of surgery of Affiliated Hospital of Hubei College of Traditional Chinese Medicine, professor, chief physician, tutor of postgraduate and doctoral student, President of Experimental Surgery Restitute Institute of Hubei College of Traditional Chinese Medicine, Director of Abdominal Tumor Surgery Research Room and Director of Anti Carcinomatous Metastasis and Reoccurrence Research Room. in addition, he held concurrent posts of Standing Director of China Medical Association Wuhan Branch, Vice President of Wuhan Micro-circulation Academy, Academic Member of International Liver Disease Research, Cooperation and Exchange Center, Member of International Surgeon Union, Standing Member of 1st, 2nd, 3rd and 4th Editorial Board of China Experimental Surgery Journal, Standing Member of 1st, 2dn and 3rd Editorial Board of Abdominal Surgery Journal. Enjoying Special Allowance of State Council.

He has been engaged in surgery work for 49 years and accumulated rich experience in radical operation of lung cancer, esophageal carcinoma, liver cancer, carcinoma of gallbladder, adenocarcinoma of pancreas, gastric carcinoma and intestinal cancer as well as in clinical therapy with Chinese Traditional Medicine combined with Western Medicine of prevention of reoccurrence and metastasis after operation.

He has been engaged in scientific research of surgery for 15 years and obtained many fruits, among which the task of Experimental Study and Clinical Application of Self-made Type XZ-C1 Abdominal Cavity–Vein Flow Turning Unit in Therapy of Chronic Ascites of Hepatic Cirrhosis issued by Science Commission of Hubei Province was awarded Second Prize of Scientific Fruit by People’s Government of Hubei Province and was popularized and applied in 38 hospitals in 12 provinces all over the country in 1982. The task Experimental Study on Physiological Mechanism and Pathogenesis of Schistosome with Method of Experimental Surgery, issued by National Natural Fund Commission was awarded Second Prize of Scientific Fruit by People’s Government of Hubei Province in 1986.

He began to study the tumor experience, established the tumor animal model and metastasis and reoccurrence animal model and probed into the mechanism and rules of carcinomatous metastasis and reoccurrence to find out the method to inhibit the metastasis. 48 kinds of Chinese traditional herbs that could counteract the intrusion, metastasis and reoccurrence were found and selected from a large number of natural herbs. Based on this, he invented and developed China Xu Ze (Z-C) Medicine Treating Malignancy, which had remarkable curative effects through over 30 years’ clinical validation of many cases.

He has been engaged in teaching for 60 years and has cultivated many young doctors, 10 masters and 2 doctors. He has released 126 papers, published New Understanding and New Mode of Therapy of Cancer as the editor in charge; participate in writing 8 medical exclusive books including Therapeutics of Liver Disease, Surgery of Liver, Gallbladder and Pancreas and Surgical Operation of Abdomen.

A Brief Introduction to the Second Author

image004.jpg

Xu Jie, male, graduated from Hubei College of Traditional Chinese Medicine in 1992, graduated from Hubei Medical University in 1996, Department of Clinical Medicine. Now He is chief physician in Hubei University of Traditional Chinese Medicine Hospital and Hubei Provincial Hospital of Surgery, engaged in experimental surgical tumor research and general surgery, urology clinical work.

Since 1992, he has been involved in the experimental tumor research of the Institute of Experimental Surgery of Hubei College of Traditional Chinese Medicine. He has carried out cancer cell transplantation and established a tumor animal model. He has carried out a series of experimental tumor research: exploring the mechanism of recurrence and metastasis of cancer and in vivo screening experiment of more than 200 kinds of Chinese herbal medicine in vivo tumor model of tumor inhibition s from a large number of natural medicine to find out, screening out of 48 kinds of anti-cancer invasion, metastasis, relapse traditional Chinese medicine

He participates in clinical validation, followed up for XZ - C immunoregulatory Chinese herbal medicine, and completes the experimental research and clinical verification, data collection, collection and summary of this book.

A brief introduction to the third author and the main translator and one of the editors

image005.jpg

Bin Wu, MD, Ph.D., graduated from College of Yunyang of Tongji University of Medical Sciences for her MD degree; Studied her Master degree and her Ph. D degree in Sun Yat-Sen University of Medical Sciences. After she received her Ph.D., she worked as a Post-doctoral Fellow in the Johns Hopkins Medical School and University of Maryland Medical School. She passed all of her USMLE tests and is going to do her residency training in America. She dedicates herself to oncology clinical and research. Her goal is to conquer cancer, which she believes that this is the great contribution to our health. She has a daughter, named Lily Xu who drew all of the graphs and the pictures in her books.

A Brief introduction to the illustrator and the advisor

image007.jpg

Lily Xu was born on November 17th 2006 in Maryland and had an art presented in the Walter Art Museum in Baltimore at the age of 6; she got the fourth place trophy in the ES Double Digits or 24 and 24 games in the Baltimore County in Maryland; she got the first trophy in the BCPS STEM FAIR PHYSICS in Baltimore County in Maryland in USA; when she was in the sixth grade, she passed the advanced Math for 7th grade(which means the 8th grade math) test and moved the 8th grade math class; she loves the reading and the writing and she finished many seires of books. She got $3000 scholarship award for the Peabody music program in the Johns Hopkins University. She edits all of my books for the publication. She is a very smart advisor on the computer and on some medical-related topics.

Foreword

Since 1985, I have conducted interviews with more than 3,000 postoperative patients who have undergone chest and abdominal cancer surgery. The results showed that most of the patients had relapsed or metastasized within 2-3 years, and some of them even relapsed, transferred and died within a few months and one year after surgery. These patients are often who did not return to the original surgery center or hospital to follow up, but to the oncology department or cancer hospital for radiotherapy and chemotherapy after surgery. Through large-scale follow-up visits, I discovered an important issue: the postoperative recurrence and metastasis are the key factors affecting the long-term efficacy of surgery. So it also raised an important question for us: studying methods to prevent and to treat the postoperative recurrence and metastasis of cancer is the key to improving the long-term efficacy of surgery, which is the key to improving the postoperative survival period of patients. Therefore, the basic clinical research to prevent the recurrence and metastasis of cancer must be conducted. If there is no breakthrough in the basic research, the clinical efficacy will hardly increase. So we set up an experimental surgical laboratory, conducted experimental tumor research, implemented cancer cell transplantation, established a tumor animal model, and conducted a series of experimental tumor studies: exploring cancer recurrence, metastasis mechanisms and patterns; exploring the relationship between tumors and immune and immune organs and the relationship between immune organs and tumors; exploring methods for suppressing progressive atrophy of immune organs and reconstructing immune function when suppressing tumor progression; finding the effective measures to regulate cancer invasion, recurrence, and metastasis; for the 200 common anti-cancer herbal medications considered in literatures, it was carried out an experimental screening of the tumor inhibition rate in the solid tumor-bearing tumor animals; the experimental study of finding the new anti-cancer, anti-metastatic and anti-relapse drugs from the natural medications. Using modern science and technology did in-depth research and explored anti-cancer Chinese herbs. It has been undergone the rigorous, scientific, and repeatable screening experiments of the tumor inhibition rate in the tumor-bearing animal models in vivo for the traditionally considered anti-cancer Chinese herbal medications. After eliminating the effect of no stabilization, 48 kinds of Z-C immunomodulatory anti-cancer medications with good curative effect were screened out. It was applied to the clinical practice based on the success of animal experiments. After the clinical verification of a large number of clinical cases in 10 years, the curative effect is significant.

Through the experimental research and clinical practice, and combined with the review, analysis, evaluation, and self-reflection of traditional method clinical practice cases over the past half century, the positive and negative experiences and lessons of clinical practice in 44 years have been summarized. There are the following points of the new discoveries, the new thinkings, the new insights and the new treatment concepts.

First, the new discoveries

1. The discovery from the results of follow-up

1). The postoperative recurrence and metastasis are the key factors that affect the long-term outcome of surgery. Therefore, we also raised an important issue: that clinicians must pay attention to and study the prevention and treatment of postoperative recurrence and metastasis, in order to improve the long-term effect after surgery.2). The clinical basic research on recurrence and metastasis must be performed. If there is no breakthrough in basic research, the clinical efficacy will be difficult to improve.

2. The discovery from the experimental tumor research

A, the removal of Thymus(TH) can produce tumor-bearing animal models and the injection of immunosuppressive agents can also contribute to the establishment of tumor-bearing animal models. The conclusions of the study clearly demonstrated that there is a clear positive relationship between the occurrence and development of cancer and the immune organs TH of the host and the function of immune organs. Without cutting TH, it is difficult to make animal models. Repeatedly repeated experiments, all confirmed the experimental results.

B, whether it is first immune low and then easy to get cancer or cancer first and then immunocompromised, our experimental results are: first immune decreases and then easy to have the occurrence and development of cancer, if the innate immune function is not reduced, it is not easy to inoculate successfully. The results of this study suggest that improving and maintaining good immune function and protecting good immune organs Thymus is one of the important measures to prevent the occurrence of cancer.

C, in our laboratory when it was studied the relationship between cancer metastasis and immune function, the animal models for the establishment of liver metastases were divided into A and B groups. Immunosuppressants were used in group A and not in group B. As a result, the number of intrahepatic metastases in group A was significantly greater than that in group B. The results of this experiment suggest that metastasis is associated with immune function, that is, immunocompromised or immunosuppressive agents may promote tumour metastasis.

D, When our laboratory examined the effects of tumors on immune organs of the body, it was found that as the cancer progressed, TH showed progressive atrophy. After the inoculation of cancer cells, the host’s Thymus showed an acute progressive atrophy, impaired cell proliferation, and significantly reduced body size. The results of this experiment suggest that tumors inhibit TH and cause atrophy of immune organs.

E, Through the experiments, we also found that: some experimental mice were not inoculated, or the tumor grew very small, then TH did not shrink significantly. In order to understand the relationship between tumor and TH atrophy, we experimented in a group of rats the transplanted solid tumor grew to the size of the thumb and was removed. After 1 month of dissection, it was found that TH did not undergo progressive atrophy. Therefore, we speculated that it is possible that solid tumors will produce a factor that is not yet known to suppress TH, and it needs to be further studied.

F, The above experimental results prove: the progress of the tumor, even if Thymus progressively shrinks, can we use some methods to prevent the shrinking of the host Thymus? Therefore, we further designed and tried to use this immune organ cell transplantation to restore experimental studies of the immune organ function. In our laboratory, we investigated the atrophy of the immune organs TH when suppressing the progression of tumors, looking for ways to restore TH function and making immune reconstitution, and using mice to carry out experimental studies on the immune function of fetal liver and spleen and thymocytes transplanted with adoptive immune system. The results showed that: S, T, and L cells were combined and transplanted.

The recent rate of complete regression of tumors was 40%, and the rate of complete regression of long-term tumors was 46.67%. Complete regression of tumors resulted in long-term survival.

G, When we examined the effects of tumors on the spleen of immune organs in the body, we found that the spleen has an inhibitory effect on tumor growth in the early stage of the tumor, and in the late stage of the tumor, the spleen also showed progressive atrophy. The results of this study suggest that the spleen has an effect on tumor growth, has a certain inhibitory effect in the early stage, and loses its inhibitory effect in the late stage. Transplantation of spleen cells can enhance tumor suppression.

H, Follow-up results suggest that control of metastasis is the key to cancer treatment. At present, it is known that there are many steps and links in cancer cell metastasis. In order to try to block one of the steps to prevent its metastasis, we consider that tumor neovascularization is one of the steps in whether cancer metastasis can take place by metastatic cancer cells. In 1986, our laboratory was carrying out microcirculation research. Microcirculation microscopy was used to observe the microvessel formation status and flow velocity of tumor nodules in transplanted cancer-bearing mice. Later, we designed anti-tumor angiogenesis drugs from natural medications. Olympus microcirculation micrography system was used to observe the process of neovascularization and to count the flow rate of arterioles and venules. The acetylcholine extract (TG) was also identified from Chinese herbal medicine. As a result, it was found that there was no neovascularization on the 1st day of inoculation, and on the 2nd day, fine neovascularization was observed. TG can reduce the density of neonatal microvessels in tumors.

I, We also found in the large number of tumor-bearing animal models in the laboratory that the solid tumors inoculated subcutaneously in some cancer-bearing mice grew bigger, and then there are the more different between the central cancerous tissue of solid tumors and the surrounding cancer cells. In the center of tumor is more for sterile necrosis or liquefaction, the surrounding is still active cancer cells. Therefore, in the clinical treatment work, we adopted measures to treat aseptic necrosis.

3. Searching for anti-cancer and anti-metastatic drugs in natural medications (TCM)

In our experimental work, our laboratory has conducted a long-term, batch-by-batch review of 200 tumor-bearing animals in the tumor-bearing animal that were traditionally considered to be anti-cancer herbs.

It was found that only 48 of them had certain or even better inhibitory effects on the proliferation of cancer cells. After optimized combination, and then by liver cancer, lung cancer, gastric cancer and other cancer-bearing animal models in vivo tumor inhibition experiments, composed of XZ-C 1-10 capsules, XZ-C 1 can significantly inhibit cancer cells, but does not affect normal cells, XZ-C4 protects Thymus and improves immune function, XZ-C8 can protect the bone marrow and improve blood, XZ-C immune regulation of traditional Chinese medications can improve the quality of life of people with advanced cancer, increase immune function, enhance physical fitness, increase appetite, and prolong survival.

4. Through the review of cases from clinical medical practice, the analysis, evaluation and reflection of postoperative adjuvant chemotherapy cases, it was found that 1, some patients failed to prevent recurrence after adjuvant chemotherapy; 2, in some patients it did not prevent metastasis after adjuvant chemotherapy; 3, in some patients Chemotherapy promotes immune failure.

5. The Analysis and Reflections of Clinical Practice Cases of why Patients’ Postoperative Chemotherapy Fails to Prevent the Recurrence and Metastasis of Cancer

From the analyze and reflect on the role of chemotherapeutic drugs in the cycle of cancer cells; from the analyze and reflect on the inhibition of the overall immune function of chemotherapeutic drugs; from the analyze and reflect on the drug resistance of chemotherapy drugs it was found that: 1. There are still some important misunderstandings in current chemotherapy; 2. There are still some major contradictions in current chemotherapy, which needs further study and improvement.

Second, to update thinking and to update understanding

Through 7 years of experimental observation in the cancer-bearing animals and the diagnosis and treatment in more than 6,000 cases in specialist out-patient clinics over the past 6 years, we have reviewed, analyzed, evaluated and self-reflected and summarized the positive and negative experiences and lessons of success and failure. Think about why traditional therapies do not significantly reduce mortality and Why the recurrence and metastasis were not controlled? What the problems with the traditional concept of traditional therapy are? I gradually realized that there may be some weak points in the current traditional cancer therapies such as:

1, The traditional chemotherapy suppresses immune function and inhibits bone marrow hematopoiesis;

2, The traditional intravenous chemotherapy is intermittent therapy, which cannot be treated during the interval. In the intermittent period, cancer cells continue to proliferate and divide;

3, The traditional treatments damage the host because chemotherapy cytotoxic drugs are double-edged swords that kill both cancer cells and normal cells;

4, The goal of traditional therapies is to focus on that chemotherapy can kill cancer cells and ignore the host’s resistance and restriction to cancer, because the occurrence and development of tumors depends on the level of host immune function and the biological characteristics of the tumor itself, that is, it depends on the comparison between the biological characteristics of tumor cells and the influence of the host on the constraint factors. If the two are balanced, they are controlled, and if the two are out of balance, they are progressing. Traditional radiotherapy and chemotherapy are all to promote the decline of immune function, which may make the two conditions more imbalanced;

5, The traditional treatment damages the central immune system. Thymus has been suppressed during cancer. And chemotherapy also suppresses bone marrow, which is more like snow adds frost and it is worst. Damage to the entire central immune system has not been effectively protected;

6, The traditional therapy is the injury therapy, which has a certain impact on the patient’s resistance to disease, but it has not been effectively protected;

7, The traditional treatments ignore the human body’s ability to fight cancer and ignore the role of anti-cancer cells in the host’s body (NK cell population, K cell population, LAK cell population, macrophage population, TK cell population). The role of the anti-cancer factor system IFN, IL-2, TNF, LT in the host body is neglected. It is gnoring the role of tumor suppressor genes and tumor suppressor genes in the host (human body has oncogenes and tumor suppressor genes, as well as cancer metastasis genes and tumor suppressor metastatic genes), and neglecting the role of the neurohumoral system and endocrine hormones in the host and ignoring the role of anti-cancer institutions and their influencing factors in the human body, as well as their role in regulating, balancing, and stabilizing the host’s body against cancer, ignoring the intrinsic factors of the body’s own anti-cancer activity that have not been activated or mobilized, but only kill cancer cells blindly.

8, The goal of traditional therapies is simpler, just kill cancer cells. Not all of them meet the actual conditions of the biological characteristics of cancers that are recognized today such as cancer cell invasiving behavior; metastatic links and multiple steps; the incentives for recurrence, latent months or lurking for several months and recurrence or relapsing in a few years. At present, people have realized that antineoplastic agents are not necessarily anti-metastatic and anti-metastatic agents are not necessarily antitumor.

Since there are the aforementioned problems, it is necessary to further study. While continuing to improve traditional therapies in accordance with